Gilead quarterly profit falls as COVID antiviral sales decrease
Reuters
Published Aug 02, 2022 21:31
Updated Aug 02, 2022 23:11
By Deena Beasley
(Reuters) -Gilead Sciences Inc on Tuesday said its second-quarter adjusted profit fell due to higher research and royalty costs as well as a downturn in sales of its COVID-19 antiviral drug Veklury.
Quarterly revenue, however, rose 1% to $6.3 billion, which was ahead of the average Wall Street estimate of $5.85 billion, according to Refinitiv data.
The biotech company said adjusted quarterly profit fell 13% to $1.58 per share, which also topped the average analyst estimate of $1.52. Net income fell to 91 cents per share from $1.21 per share.
Sales of COVID-19 treatment remdesivir, which is sold under the brand name Veklury, fell 46% to $445 million, but still came in ahead of analysts' estimates of $390 million.
"Sales declined as hospitalization rates declined in most geographies," Gilead (NASDAQ:GILD) Chief Commercial Officer Johanna Mercier said on a conference call, adding the company remains ready to supply Veklury if needed.
Cancer drug Trodelvy - shown in a recent trial to modestly delay tumor growth in women with the most common form of breast cancer - saw sales rise 79% to $159 million. Sales of Gilead's cancer cell therapies rose by a robust 68% to $368 million.
HIV drug sales, driven by demand for higher-priced products, rose 7% to $4.2 billion.
Gilead announced that the U.S. Food and Drug Administration will decide by Dec. 27 whether to approve its long-acting HIV medication lenacapavir.
"We’ve seen somewhat of a recovery in core products from last quarter’s weaker results," BMO Capital Markets analyst Evan Seigerman said in a research note. He pointed to particular strength in HIV and cell therapy products.
For full-year 2022, California-based Gilead sightly raised its forecast for adjusted earnings per share to between $6.35 to $6.75 from a previous view of $6.20 to $6.70. Gilead said it now expects product sales of $24.5 billion to $25 billion, up from a prior estimate of $23.8 billion to $24.3 billion.
Gilead were up 1% at $60.15 in after hours trading.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.